JAC Advance Access originally published online on February 14, 2006
Journal of Antimicrobial Chemotherapy 2006 57(4):750-752; doi:10.1093/jac/dkl019
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Heterogeneity of metallo-ß-lactamases in clinical isolates of Chryseobacterium meningosepticum from Hangzhou, China
2nd Affiliated Hospital of Zhejiang University, Zhejiang University, 88 JieFang Rd, Hangzhou 310009, China
* Corresponding author. Tel: +86-571-8778-4633; Fax: +86-571-8782-4695; E-mail: chengong218{at}163.com
Received 15 November 2005; returned 20 November 2005; revised 11 January 2006; accepted 13 January 2006
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and methodsResults and discussionTransparency declarationsReferences |
|---|
Objectives: To determine the distribution and heterogeneity of metallo-ß-lactamases (MBLs) responsible for imipenem resistance in Chryseobacterium meningosepticum.
Methods: Clinical C. meningosepticum isolates (n = 170) were collected from hospitals in Hangzhou, China. Production of MBLs was investigated by determination of imipenem MICs, and by using both a three-dimensional test and a 2-mercaptopropionic acid inhibitory test. Genes encoding BlaB and GOB MBLs were amplified by PCR, sequenced and compared with genes in GenBank.
Results: More than 95% of the 170 isolates showed high (MIC > 16 mg/L) or intermediate resistance to imipenem, but only 94 isolates (55%) were shown phenotypically to produce MBLs (imipenem MIC range, 8–256 mg/L), with MBL genes detected in 93 of these. Among them, 83 isolates had blaB alleles and 65 isolates had blaGOB alleles; 38 isolates possessed one MBL gene and 55 isolates contained two genes. The major blaB alleles encoded BlaB-2, -3 and -11, while the major blaGOB alleles encoded GOB-2, -4, -8 and -10. MBLs or their genes were not detected in 76 (45%) isolates, including many that were highly resistant to imipenem.
Conclusions: High levels and rates of imipenem resistance in C. meningosepticum from Hangzhou often result from the presence of heterogeneous BlaB and/or GOB MBLs, although undefined carbapenem resistance mechanisms also exist. Susceptibility testing and screening for MBLs should be conducted in order to inform effective treatment for C. meningosepticum infections.
Keywords: imipenem , resistance , genotypes , phenotypes
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and methodsResults and discussionTransparency declarationsReferences |
|---|
Chryseobacterium meningosepticum is the most clinically important species of the genus Chryseobacterium, causing neonatal meningitis, pneumonia, sepsis and soft tissue and other tissue infections. The mortality rate for neonatal meningitis can be as high as 57%.1 Chryseobacteria are resistant to multiple antibiotics, especially to ß-lactams.1,2 Many possess two different types of ß-lactamases, namely class A extended-spectrum ß-lactamases and class B metallo-ß-lactamases (MBLs); the latter confer resistance to carbapenems, which are widely used to treat infections caused by multidrug-resistant Gram-negative bacteria.3–5
Two types of MBL, BlaB and GOB, have been identified in isolates of C. meningosepticum.1,6 Although they have similar molecular weights and pIs, these two enzyme types show only very low molecular similarity.1,7 Sequencing and analysis of genes encoding BlaB and GOB has revealed heterogeneity, with up to 12 blaGOB and 14 blaB alleles identified and registered in GenBank.1,6 However, there have been no systematic studies to determine the distribution and heterogeneity of BlaB versus GOB MBLs in a large collection of clinical isolates of C. meningosepticum.
In this study, we collected a large number of clinical isolates of antibiotic-resistant C. meningosepticum from hospitals in Hangzhou, China, and sought MBLs by phenotypic methods. The genotypes and heterogeneity of genes encoding MBLs were also analysed.
|
Materials and methods |
|---|
|
TopAbstractIntroductionMaterials and methodsResults and discussionTransparency declarationsReferences |
|---|
Bacterial strains
Clinical isolates of C. meningosepticum (n = 170) were collected from major hospitals in Hangzhou, China. Identification and susceptibility testing was conducted using automated systems (VITEK, BioMerieux, Marcy l'Etoile, France and/or Phoenix, Becton Dickinson, MD, USA). The MICs of a range of antibiotics were determined using the agar dilution method according to CLSI (NCCLS) recommendations.
Screening and confirmation of MBLs
Two phenotypic methods were used to screen isolates for MBLs. For the three-dimensional (3-D) tests, crude enzyme extracts were prepared from isolates by repeated freeze-thawing.8 Both crude enzyme extract (40 µL) only, and enzyme extract (30 µL) plus 10 µL of 0.3 M EDTA were loaded in slots in a plate of Mueller–Hinton agar, in the centre of which was placed a paper disc containing 10 µg of imipenem (Oxoid, Basingstoke, UK). Escherichia coli ATCC 25922 was inoculated as the indicator isolate. After overnight incubation, extracts that gave larger inhibition zones in the presence of EDTA and showed growth in the absence of EDTA were judged to contain MBLs. Production of MBLs was confirmed by the method developed by Arakawa et al.9 Two imipenem discs were placed on a Mueller–Hinton agar plate on to which a C. meningosepticum isolate was spread. A filter paper disc containing 3 µL of 2-mercaptopropionic acid was placed adjacent to one imipenem disc. MBL production was assessed after incubation at 35°C for 18–24 h, and judged positive if the imipenem inhibition zone was enlarged on the side toward the 2-mercaptopropionic acid disc.
PCR amplification and sequencing of bla genes
Consensus primer pairs that detect all reported blaB and blaGOB MBL genes were used for PCR amplification of the target genes.4–6 The PCR products were cloned into a pGEM-T-easy-Vector (Promega, Madison, USA) and recombinant plasmids were transformed into E. coli DH5
. The transformants were selected on ampicillin-containing (50 mg/L) Luria–Bertani agar plates. Inserts were sequenced using an ABIPRISM 377 DNA Sequencer (ABI, MN, USA) and results were compared with existing blaB and blaGOB sequences in the GenBank database.
|
Results and discussion |
|---|
|
TopAbstractIntroductionMaterials and methodsResults and discussionTransparency declarationsReferences |
|---|
Screening C. meningosepticum isolates for phenotypic MBL production
The susceptibilities of C. meningosepticum isolates to imipenem and 13 other antibiotics were determined. The distribution of imipenem MICs for the 170 isolates is shown in Figure 1. Only eight (4.6%) isolates were susceptible to imipenem in vitro (MICs 
4 mg/L), while 140 (>76%) isolates were highly resistant (MICs 
16 mg/L) (Figure 1). The proportion of imipenem-resistant C. meningosepticum isolates in our collection was higher than has been reported from hospitals in other parts of the world.10 However, only 94 (55%) isolates produced metallo-carbapenemases as determined by the 3-D test and a 2-mercaptopropionic acid inhibitory test.8,9
|
PCR amplification and heterogeneity of MBL genes
We amplified blaB and/or blaGOB sequences from 93 of the 94 C. meningosepticum isolates that were phenotypic MBL producers (Table 1); 83 isolates had blaB alleles and 65 had blaGOB alleles. The major blaB genotypes encoded BlaB-2 (43%), -3 (20%) and -11 (26%) enzymes, while the major blaGOB genotypes encoded GOB-2, -4, -8 and -10; GOB-8 and GOB-10 composed 61.5% (40/65) of all GOB types. MBLs were detected in isolates over a wide range of imipenem MICs (8–256 mg/L; Figure 1). Thirty-eight isolates possessed one MBL gene and 55 isolates contained two distinct MBL genes, which may contribute to the high-level imipenem resistance of some isolates.
|
The distribution of bla genotypes varied in isolates from different hospitals (data not shown). The majority of GOB-producers from the Municipal TCM Hospital of Hangzhou had GOB-8, while all BlaB-producers had BlaB-2, which is consistent with the spread of common strains. On the other hand, the MBLs in isolates from the 2nd Affiliated Hospital showed greater heterogeneity; GOB-8, -4, -2 and -1, which were all identified in isolates from other hospitals, and also GOB-6 and GOB-5, which were not detected in other hospitals.
Novel mechanisms of carbapenem resistance
We found no phenotypic evidence of MBL production for 76 (45%) C. meningosepticum isolates, and failed to amplify either blaB or blaGOB sequences, even though many of these isolates were highly resistant to imipenem (Figure 1). These results suggest the presence of other carbapenem resistance mechanisms in C. meningosepticum isolates from Hangzhou.
It is clear that C. meningosepticum isolates from Hangzhou are highly resistant to imipenem, and that many isolates produce BlaB- and/or GOB-type MBLs. Therefore, in cases of serious infection by C. meningosepticum, susceptibility testing and screening for MBLs should be conducted in order to inform effective treatment. Carbapenems, which are widely used for the treatment of Gram-negative bacteria including Chryseobacteria, may not be a good choice for C. meningosepticum. Isolates from our region show greater susceptibility to combinations of cefoperazone/sulbactam (70–85%), piperacillin/tazobactam (65–80%) and trimethoprim/sulfamethoxazole (50–70%) in vitro (data not shown). These agents may be more effective options and have been used in our hospital for C. meningosepticum infection. In addition, vancomycin and rifampicin, which are more frequently used for Gram-positive bacteria, are an even better choice (not shown).10
|
Transparency declarations |
|---|
|
TopAbstractIntroductionMaterials and methodsResults and discussionTransparency declarationsReferences |
|---|
None to declare.
|
References |
|---|
|
TopAbstractIntroductionMaterials and methodsResults and discussionTransparency declarationsReferences |
|---|
1. Bellais S, Aubert D, Naas T et al. Molecular and biochemical heterogeneity of class B carbapenem-hydrolyzing ß-lactamases in Chryseobacterium meningosepticum. Antimicrob Agents Chemother 2000; 44: 1878–86.
2. Bellais S, Leotard S, Poirdl L et al. Molecular characterization of a carbapenem-hydrolyzing ß-lactamase from Charyseobacterium (Flavobacterium) indologenes. FEMS Microbiol Lett 1999; 171: 127–32.[ISI][Medline]
3.
Bellais S, Poirel L, Naas T et al. Genetic-biochemical analysis and distribution of the Ambler class A ß-lactamase CME-2, responsible for extended-spectrum cephalosporin resistance in Chryseobacterium (Flavobacterium) meningosepticum. Antimicrob Agents Chemother 2000; 44: 1–9.
4. Rossolini GM, Franceschini N, Riccio ML et al. Characterization and sequence of the Chryseobacterium (Flavobacterium) meningosepticum carbapenemase: a new molecular class B ß-lactamase showing a broad substrate profile. Biochem J 1998; 332: 145–52.
5.
Rossolini GM, Franceschini N, Laurettil L et al. Cloning of a Chryseobacterium (Flavobacterium) meningosepticum chromosomal gene (blaACME) encoding an extended-spectrum class A ß-lactamase related to the Bacteroides cephalosporinases and the VEB-1 and PER ß-lactamases. Antimicrob Agents Chemother 1999; 43: 2193–99.
6.
Woodford N, Palepou MF, Babini GS et al. Carbapenemases of Chryseobacterium (Flavobacterium) meningosepticum: distribution of blaB and characterization of a novel metallo-ß-lactamase gene, blaB3, in the type strain, NCTC 10016. Antimicrob Agents Chemother 2000; 44: 1448–52.
7.
Vessillier S, Docquier JD, Rival S et al. Overproduction and biochemical characterization of the Chryseobacterium meningosepticum BlaB metallo-ß-lactamase. Antimicrob Agents Chemother 2002; 46: 1921–27.
8.
Manchanda V, Singh NP. Occurrence and detection of AmpC ß-lactamase among Gram-negative clinical isolates using a modified three-dimensional test at Guru Tegh Bahadur Hospital, Delhi, India. J Antimicrob Chemother 2003; 51: 415–8.
9.
Arakawa Y, Shibata N, Shibayama K et al. Convenient test for screening metallo-ß-lactamase-producing Gram-negative bacteria by using thiol compounds. J Clin Microbiol 2000; 38: 40–3.
10.
Kirby JT, Sader HS, Walsh TR et al. Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp.: report from the SENTRY antimicrobial surveillance program (1997–2001). J Clin Microbiol 2004; 42: 445–8.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. C. Cai, H. W. Zhou, R. Zhang, and G.-X. Chen Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates Possessing the Plasmid-Mediated Carbapenem-Hydrolyzing {beta}-Lactamase KPC-2 in Intensive Care Units of a Chinese Hospital Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2014 - 2018. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zhang, L. Yang, J. C. Cai, H. W. Zhou, and G.-X. Chen High-level carbapenem resistance in a Citrobacter freundii clinical isolate is due to a combination of KPC-2 production and decreased porin expression J. Med. Microbiol., March 1, 2008; 57(3): 332 - 337. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||